[Comunicado de imprensa – Ainda não publicado] Dados atualizados sobre a nova pílula da Merck contra Covid (molnupiravir) mostram eficácia reduzida (30%) em evitar internação e morte, em comparação aos resultados iniciais (50%). O risco absoluto em reduzir internação e morte caiu de 7% para 3%.

Comunicado de imprensa: Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19

Comentário: New data, analyses take some of the shine off Merck’s Covid pill – STAT

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Comentários no Twitter

Disappointing!!
💥Merck Provides Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
N=1433
RRR fell from 50% to 30%
Absolute Risk reduction only 3% #IDTwitter https://t.co/aX2b3xrdnB pic.twitter.com/uXUSQRNWC7

— Antibiotic Stewa®️x🆔 Bassam Ghanem (@ABsteward) November 26, 2021

Disappointing from Merck. Updated data for efficacy of their Molnupiravir pill in full trial drops down to 30% from 50%, absolute reduction to 3 from 7 per 100 at interim analysis https://t.co/PyfIBnFNC7 pic.twitter.com/SBDL92aG5M

— Eric Topol (@EricTopol) November 26, 2021